 Your new post is loading...
Scoop.it!
Mitral valve is a part of the heart which is located in the left region. It is actually a link that connects the atrium and ventricle. For people with normal body conditions, this valve is a responsible link for controlling blood rotation in different heart chambers. However the problem arises when a valve balloons out, which is called prolapse syndrome condition in the mitral valve. 
No comment yet.
Sign up to comment
Scoop.it!
Did you know that the most common type of heart valve disorder is mitral regurgitation, sometimes called a “leaky valve”? This happens when the valve between the upper and lower chambers on the left side of the heart do not close properly, which can cause a decrease in blood flow to the rest of the body.
Scoop.it!
Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve, providing a minimally invasive treatment option for patients whose surgical mitral or aortic valves require replacement, and who are at extreme risk for surgery.
Scoop.it!
Understand mitral valve stenosis and regurgitation with this clear explanation by Dr. Roger Seheult. Includes discussion on the signs and symptoms, diagnosis...
Scoop.it!
Rupture of the left ventricle after mitral valve replacement, although infrequent, may be a highly lethal complication. This report describes the early diagnosis and successful repair of rupture of atrioventricular groove in an elderly patient who underwent mitral valve replacement.
Scoop.it!
Dr. David Theodoro of the SSM Heart Institute discusses Mitral Valve Stenosis. This tightening or stiffening of the heart valve often leads to surgical treatment. Dr. Theodoro discusses the causes, effects and treatment options, including minimally invasive valve replacement surgery.
Scoop.it!
Neovasc Inc. (TSXV: NVC) today announced that a first-in-human implantation of its Tiara(TM) transcatheter mitral valve was successfully performed on January 30(th) by physicians at St. Paul's Hospital in Vancouver, BC. The transapical procedure resulted in the elimination of mitral regurgitation (MR) and significantly improved heart function in the patient, without the need for cardiac bypass support and with no procedural complications.
Scoop.it!
Prosthetic heart valves, due to the continuous stress they're subjected to, have a limited lifetime and may even require replacement once worn out. Edwards Lifesciences just received European CE Mark approval to offer the SAPIEN XT transcatheter valve for valve-in-valve procedures. The SAPIEN XT is indicated for implantation inside both mitral and aortic valves, and can reside on top of a previously installed prosthetic valve.
Scoop.it!
Doctors at Henry Ford Hospital in Detroit used an Edwards Lifesciences Sapien transcatheter aortic valve replacement (TAVR) device to repair a mitral valve that was narrowed with calcium buildup.
Scoop.it!
Most rheumatic mitral valves have undergone replacement in recent years, but replacement mortality remains significant at a time when repair mortality is approaching zero. Therefore, an effort was made to increase repair rates and efficacy in a single surgeon series of patients having operation for rheumatic mitral valve disease.
Scoop.it!
Scientists also found that gene disrupts heart valve development & growth Research on the DNA of a large multi-generational family has provided a genetic clue that enabled scientists to pinpoint a gene that plays a role in mitral valve prolapse (MVP), a common cardiac disease that is a leading cause of heart failure, according to …
Scoop.it!
This year has been a great one in the area of cardiovascular disease. There have been tremendous advances in prevention, treatments, and less invasive procedures. Here are 10 of the studies that really impacted our knowledge or approaches to patient care this year.
Scoop.it!
“I went from being 25 percent operational to 100 percent,” said Hothan. MVR can seem a miraculous procedure to patients who, like Hothan, have been struggling for years.
Scoop.it!
A new study shows that a tissue valve can be implanted with vascular cells and become alive and self repair in the setting of daily use. Even more excite these valve can be placed without open heart surgery.
Scoop.it!
Leading the development of transcatheter mitral valve replacement therapies is one of Edwards Lifesciences’ strategic imperatives, the company explained during its recent investor conference. The potential market is large, but so are the technical hurdles. Medtronic and other smaller players are also taking steps.
Scoop.it!
Thoracic Surgery News, the official newspaper of the American Association for Thoracic Surgery - now published 10 times per year! This publication will include sections devoted to the news of general thoracic surgery, adult cardiac surgery, transplantation, and congenital heart disease. Content for Thoracic Surgery News is provided primarily by the Elsevier Society News Group/Elsevier Global Medical News and by the American Association of Thoracic Surgery.
Scoop.it!
Still, the authors acknowledge several challenges. First, “the ideal device must be stable and resistant to displacement or migration while enduring continuous cyclical movements of the mitral annulus and the base of the heart, as well as the high pressure gradients that are generated across the mitral valve,” they observe. Valve materials must also be “durable enough to withstand the loads generated.”
Scoop.it!
A preclinical study to be published in the February issue of JACC: Cardiovascular Interventions describes results of the implantation of Neovasc Inc.'s (Vancouver, BC, Canada) Tiara mitral valve device. Tiara is intended to be an alternative to open mitral valve repair or replacement for patients with mitral valve regurgitation who pose an unacceptable risk for surgery.
Scoop.it!
A short presentation on some of the techniques used to address MAC (mitral annular calcification) is followed by an operative video demonstrating several of the techniques. Techniques include mechanical debridement, CUSA debridement, supra-annular MVR, and infra-annular MVR.
Scoop.it!
In a paper recently published in the Journal of the American College of Cardiology, experts provided an overview of where we’re at regarding minimally-invasive therapies for the treatment of mitral regurgitation. They reviewed the latest research on the topic and provided recommendations for making minimally-invasive therapies a reality for the treatment of this condition.
Scoop.it!
A new clinical study has determined that in patients with ischemic mitral regurgitation (IMR), there is no significant difference between repairing a leaky mitral valve or replacing it with a prosthetic valve. The study was carried out by the Cardiothoracic Surgical Trials Network (CTSN), a consortium supported by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), along with the Canadian Institutes of Health Research (CIHR).
Scoop.it!
From
w
“WIPO patent: Disclosed are prosthetic mitral valves as well as methods and devices suitable for deploying prosthetic mitral valves.”
Scoop.it!
“Guidance for Transcatheter Mitral Regurgitation Treatment Issued Doctors Lounge Protocols should include assessment of the structure and function of the mitral valve, cardiac chamber sizes, biventricular function, pulmonary artery pressures, and...”
Scoop.it!
Four cardiovascular professional societies have laid out the key issues facing the evolving field of transcatheter therapies for mitral valve regurgitation. The document, published online November 25, 2013, ahead of print in the Journal of the American College of Cardiology, provides a framework for discussion by the various stakeholders and future development of guidelines aimed at appropriate integration of the procedures into patient care.
Scoop.it!
The Cardiothoracic Surgical Trials Network (CTSN), whose Data and Clinical Coordinating Center is at Icahn School of Medicine at Mount Sinai, is reporting for the first time evidence on whether or not there is any significant difference between the two current surgical approaches to treat patients with severe ischemic mitral regurgitation — mitral valve repair and mitral valve replacement.
|
Curated by Beeyond
BEEYOND is a consulting company in the field of disruptive innovation, accompanying established companies on out-of-the-core growth strategy, from creation of new concepts to product launch. Reach us at: contact@beeyond.fr.
Other Topics
#dotdot, the community internet
Aidants
Aston-Martin
Augmented & Virtual Reality
Blue Ocean Strategy
Brain Computer Interfaces & connected medical devices
Consumer Digital Health
Covid-19, SARS-Cov-2, vaccines, Remdesivir, Chloroquine...and all that Jazz
Critical Limb-Threatening Ischemia (CLTI)
Daily realities of diabetic patients
Fashion & technology
Healthcare: reloaded...
High level trending in...
In-Vitro Diagnostic
Innovating to what's next...
Instrumental cosmetics
Interventional Cardiology
Intra-Dermal drug delivery: Opportunities and Challenges?
Local delivery for Gene Directed Enzyme Prodrug Therapy
Engineered MSCs with suicide genes delivered intra-arterially to treat various cancers. Local delivery bypasses homing issues that plagued prior GDEPT programs.
Metabolic Activation Therapy
Neurovascular Intervention
Nudges
Peritoneal dialysis
Sclérose en Plaques
Solid tumors: latest on treaments and research pathways
glioblastoma, craniopharyngioma...
Tailored Expertise Sourcing & Market Intelligence in Global Consulting
The future of e-cigarette
The Revolution Of The Car Industry
Track & Trace
Transcatheter Treatment of Mitral Regurgitation
|
